Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
J Cell Mol Med. 2022 Jun;26(12):3506-3512. doi: 10.1111/jcmm.17390. Epub 2022 May 24.
Programmed death-ligand 1 (PD-L1) is involved in immunosuppression in variety of tumours. Regulatory B cells (Bregs) are critical immune regulatory cells, and it has been demonstrated that the number of regulatory B cells in patients with acute myeloid leukaemia (AML) is much higher than that in healthy donors (HDs), which is linked to a poor prognosis. This study aimed to determine whether increased expression of PD-L1, including in Bregs, is associated with a worse prognosis in individuals with AML. The proportion of Bregs, PD-L1 expression in Bregs and PD-1 expression in T cells were determined using flow cytometry using patient samples from 21 newly diagnosed AML patients at different stages of treatment and 25 HDs. We confirmed PD-L1 expression in Bregs, and PD-1 expression in CD3 CD4 T cells in bone marrow and peripheral blood samples from AML patients was higher than that in samples from HDs. The complete remission (CR) and progression-free survival (PFS) of Bregs with high PD-L1 expression were significantly decreased following induction chemotherapy. PD-L1 expression is indeed increased in Bregs from individuals with AML, and high PD-L1 expression is related to a poor prognosis.
程序性死亡配体 1（PD-L1）参与多种肿瘤的免疫抑制。调节性 B 细胞（Bregs）是重要的免疫调节细胞，已经证明急性髓系白血病（AML）患者的调节性 B 细胞数量高于健康供体（HDs），这与预后不良有关。本研究旨在确定 PD-L1 的表达增加，包括 Bregs 中的表达，是否与 AML 患者的预后不良相关。使用流式细胞术，使用 21 名处于不同治疗阶段的新诊断 AML 患者和 25 名 HDs 的患者样本，确定了 Bregs 的比例、Bregs 中的 PD-L1 表达和 T 细胞中的 PD-1 表达。我们证实了 AML 患者骨髓和外周血样本中 Bregs 中的 PD-L1 表达和 CD3 CD4 T 细胞中的 PD-1 表达高于 HDs 样本中的表达。诱导化疗后，高 PD-L1 表达的 Bregs 的完全缓解（CR）和无进展生存期（PFS）显著降低。AML 患者的 Bregs 中确实存在 PD-L1 表达增加，高 PD-L1 表达与预后不良相关。
